211053-49-5

Basic information

• Product Name: 3(R)-HYDROXYMETHYLMORPHOLINE
• Synonyms: 3(R)-HYDROXYMETHYLMORPHOLINE;3(R)-HYDROXYMETHYLMORPHOLINE HCL,;(R)-3-Hydroxymethylmorpholine;(R)-morpholin-3-ylmethanol;((3R)-Morpholin-3-yl)methanol;(3R)-3-Morpholinemethanol;3(R)-Hydroxymethylmorpholine hydrochloride;(R)-3-Morpholinemethanol
• CAS NO: 211053-49-5
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Product Categories: pharmacetical;Chiral Reagents;Heterocycles
• Mol File: 211053-49-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 78-81°C
• Boiling Point: 218℃
• Flash Point: 86℃
• Appearance: White to off-white solid
• Density: 1.045
• Vapor Pressure: 0.0268mmHg at 25°C
• Refractive Index: 1.441
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 3(R)-HYDROXYMETHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3(R)-HYDROXYMETHYLMORPHOLINE(211053-49-5)
• EPA Substance Registry System: 3(R)-HYDROXYMETHYLMORPHOLINE(211053-49-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 211053-49-5(Hazardous Substances Data)

Usage

Chemical Properties

White to Off-White Solid

Uses

Different sources of media describe the Uses of 211053-49-5 differently. You can refer to the following data:
1. A chiral morpholine drivative.
2. A chiral morpholine drivative

InChI:InChI=1/C5H11NO2/c7-3-5-4-8-2-1-6-5/h5-7H,1-4H2/t5-/m1/s1

Upstream product

• 106973-37-9 (3S)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 
• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 

Downstream Products

• 1266238-75-8 (S)-4-benzyl-3-(fluoromethyl)morpholine 
• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 
• 696582-88-4 (R)-3-(methoxymethyl)morpholine 
• 1445591-33-2 (R)-benzyl 3-(methoxymethyl)morpholine-4-carboxylate 
• 1445590-49-7 ((1,2-trans)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((S)-3-(tert-butoxymethyl)morpholino)methanone 
• 1445591-28-5 (S)-benzyl 3-(tert-butoxymethyl) morpholine-4-carboxylate 
• 441717-93-7 (R)-benzyl 3-(hydroxymethyl)morpholine-4-carboxylate 
• 917572-35-1 {(3R)-4-[1-(diphenylmethyl)azetidin-3-yl]morpholin-3-yl}methanol 

Relevant articles and documents

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

The application relates to new piperazine- or morpholine-substituted azetidine derivatives of formula I. These compounds are antagonists at the neurokinin receptor and can be used for the treatment of gastrointestinal diseases. The application also relate